Late and Undocumented Insulin Administration for Two Diabetic Residents
Summary
The deficiency involves the facility’s failure to provide pharmaceutical services that ensured accurate and timely administration and documentation of insulin for two residents with Type 2 Diabetes Mellitus. For the first resident, a male with diabetes, CVA, legal blindness, and a left below-knee amputation, the MARs for February through April 2026 showed repeated late administration of ordered insulin doses. His orders included Insulin Glargine 22 units subcutaneously at bedtime and NovoLOG on a sliding scale before meals (and previously at bedtime). Documentation showed that on multiple dates in February and March, insulin doses scheduled for 8:00 p.m. were recorded as administered more than one hour late, such as at 9:41 p.m. and 9:19 p.m. in February and at 9:22 p.m. and 9:42 p.m. in March. In April, the same bedtime Insulin Glargine order was documented as given at 9:02 p.m. and 9:01 p.m. instead of the scheduled 8:00 p.m. For this first resident, the facility’s records did not contain progress notes identifying these late administrations as medication errors, nor any documentation of provider notification or management notification related to the late insulin doses between February 1 and April 30, 2026. The resident’s care plan identified a history of Type 2 Diabetes Mellitus, and the MDS documented that he required insulin injections and had intact cognition. Despite this, there was no corresponding clinical documentation explaining the deviations from ordered administration times or any nursing assessment or follow-up related to the late insulin administration. The second resident, a female with diabetes, major depressive disorder, and bipolar disorder, also had physician orders for insulin that were not followed as written. Her orders included Insulin Glargine-yfgn 20 units subcutaneously at bedtime, to be held if blood sugar was less than 150, and NovoLOG FlexPen on a sliding scale before meals and at bedtime, also to be held if blood sugar was less than 150. The April 2026 MAR showed that the Insulin Glargine-yfgn scheduled for 6:00 p.m. was documented as administered at approximately 9:00 p.m. on multiple dates, and the NovoLOG FlexPen scheduled for 8:00 p.m. was also documented as given around 9:00 p.m. on several dates. As with the first resident, there were no progress notes identifying these late administrations as medication errors, no documentation of provider notification, and no indication that facility management was informed. Interviews with medication aides, an RN, ADONs, the DON, and the Administrator confirmed that the facility’s protocol required medications to be administered within one hour before or one hour after the scheduled time, and that doses given outside this window were considered medication errors requiring immediate reporting, provider notification, and progress note documentation. Staff stated that late doses should be documented with reasons in the progress notes and reported to the DON or ADON. The ADONs and DON acknowledged that they could pull reports to identify out-of-range administration times, and that late doses should trigger follow-up. However, the ADONs reported they were not aware of the late insulin administrations and had not counseled the nurse involved, and Human Resources confirmed that the LVN associated with numerous late entries had not been counseled. The DON stated she was aware of late entries by this LVN and attributed some late documentation to the LVN not interrupting residents, but there was no evidence of corrective documentation or reporting in the residents’ records. Facility policies and in-service materials emphasized the right time and immediate documentation as part of the rights of medication administration, but these were not followed in the cases reviewed.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.